This article is more than 5 years old. Information may no longer be current.

High SVR rates met among HCV patients in ION-2

CHICAGO — HCV Next Editorial Board member Paul Y. Kwo, MD, professor of medicine and director of liver transplantation at Indiana University, discusses the ION-2 study that demonstrated success with a fixed-dose treatment of ledipasvir (Gilead) and sofosbuvir (Sovaldi, Gilead) for patients with HCV genotype 1.

The treatment was successful as a 12-week regimen without the need for ribavirin, with an SVR12 rate of 94%. Patients with cirrhosis saw an SVR12 rate of 86%, which climbed to 100% with 24 weeks of treatment.

“This represents a substantial advancement and provides the first treatment option that will likely be FDA approved for treatment of those who have failed the first-generation protease inhibitors,” Kwo told Healio.com.